<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966663</url>
  </required_header>
  <id_info>
    <org_study_id>CtDNA Lung RCT</org_study_id>
    <nct_id>NCT04966663</nct_id>
  </id_info>
  <brief_title>Using ctDNA to Determine Therapies for Lung Cancer</brief_title>
  <acronym>ctDNA Lung RCT</acronym>
  <official_title>From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the&#xD;
      blood can help to predict whether giving adjuvant treatment after surgery can decrease the&#xD;
      chance of the cancer coming back in people with lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For people who have early stage non-small cell lung cancer (NSCLC), the usual treatment is&#xD;
      surgery. For many people, surgery is enough to get rid of all the cancer. However, for some&#xD;
      people, there may be a little bit of cancer remaining. If there is some cancer left over, it&#xD;
      may lead to the cancer regrowing. This is called relapse.&#xD;
&#xD;
      Many cancers shed little bits of their DNA (deoxyribonucleic acid, molecules that contain&#xD;
      instructions for how cells develop and function) into the bloodstream. A blood test can be&#xD;
      used to test for the amount of circulating tumour DNA (ctDNA). Some studies have shown that&#xD;
      the presence of ctDNA in the blood may predict cancer recurrence.&#xD;
&#xD;
      The purpose of this research study is to see if adjuvant treatment (additional treatment&#xD;
      given after primary treatment) can help decrease the risk of the cancer recurring in people&#xD;
      with lung cancer who have ctDNA detected in their blood after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of ctDNA clearance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Complete Surgical Resection</condition>
  <condition>Circulating Tumor DNA</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will have blood taken for ctDNA testing.&#xD;
A cycle is 21 days. Pemetrexed (for participants with non-squamous non-small cell lung cancer), intravenously (by vein) on Day 1 of Cycles 1-4, OR gemcitabine (for all other participants) on Days 1 and 8 of Cycles 1-4.&#xD;
Cisplatin*, intravenously (by vein) on Day 1 of Cycles 1-4 Nivolumab, intravenously (by vein) on Day 1 of Cycles 1-4&#xD;
*If cisplatin is not tolerated, carboplatin may be given instead</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will have blood taken for ctDNA testing.&#xD;
Participants will be followed as per standard of care every 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Antineoplastic agent</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Antineoplastic agent</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Antineoplastic agent</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Antineoplastic agent</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Antineoplastic agent</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ctDNA blood test</intervention_name>
    <description>Blood will be collected for ctDNA testing</description>
    <arm_group_label>Adjuvant chemo-immunotherapy therapy</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years at the time of screening&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to performing any&#xD;
             protocol-related procedures&#xD;
&#xD;
          -  Complete surgical resection of T1-2N0M0 or T3/T4 multifocal non-small cell lung cancer&#xD;
&#xD;
          -  Any pathologic subtype of non-small cell lung cancer is eligible, including&#xD;
             adenocarcinoma and squamous carcinoma. Patients with targetable genomic alterations&#xD;
             without approved or available targeted adjuvant therapy options are eligible&#xD;
&#xD;
          -  Patients with evidence of minimal residual disease based on detectable plasma ctDNA at&#xD;
             3-6 weeks post complete surgical resection are eligible.&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected&#xD;
             non-small cell lung cancer&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants that should receive adjuvant chemotherapy per standard of care&#xD;
&#xD;
          -  Receipt of any conventional or investigational anticancer therapy within 21 days or&#xD;
             radiotherapy within 14 days prior to the scheduled first dose of study treatment&#xD;
&#xD;
          -  Prior receipt of any immune-mediated anti-cancer therapies&#xD;
&#xD;
          -  Incomplete surgical resection&#xD;
&#xD;
          -  Concurrent enrolment in another therapeutic clinical study of systemic anti-cancer&#xD;
             treatment. Enrolment in observational or supportive studies will be allowed&#xD;
&#xD;
          -  Subjects with a recent history of myocardial infarction, congestive heart failure ≥&#xD;
             Class 3 based on New York Heart Association Functional Classification or stroke within&#xD;
             the past 3 months prior to the scheduled first dose of study treatment&#xD;
&#xD;
          -  Active autoimmune disorders within the past 3 years prior to the scheduled first dose&#xD;
             of study treatment&#xD;
&#xD;
          -  Have known uncontrolled human immunodeficiency virus (HIV)-1/2 infection&#xD;
&#xD;
          -  History of primary immunodeficiency, solid organ transplantation, or active&#xD;
             tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Leighl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natasha Leighl, M.D.</last_name>
    <phone>416-946-4645</phone>
    <email>Natasha.Leighl@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Natasha Leighl, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

